Pfizer’s PARP Inhibitor, RSV Vaccine, Lilly’s IL-13 Med UP for Panel Review on Nov. 27

November 14, 2023
A key health ministry advisory panel will discuss whether to recommend approval for a batch of new medicines at an upcoming meeting on November 27, including Pfizer’s PARP inhibitor and respiratory syncytial virus (RSV) vaccine as well as Eli Lilly’s...read more